Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 4/20 | 0.62 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.38 |
| ▸ | HTR1A | P08908 | 5/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbamic Acid SCHEMBL5746918 | 0.94 | SLC2A1 (0.57) | SLC2A1TRPC6KCNH2HTR1ASLC6A4 | |
| SCHEMBL5746290 | 0.91 | SLC2A1 (0.51) | SLC2A1TRPC6KCNH2HTR1ASLC6A4 | |
| SCHEMBL6079876 | 0.89 | SLC2A1 (0.56) | SLC2A1TRPC6KCNH2HTR1ASLC6A4 | |
| SCHEMBL6079870 | 0.89 | SLC2A1 (0.56) | SLC2A1TRPC6KCNH2HTR1ASLC6A4 | |
| SCHEMBL6079872 | 0.89 | SLC2A1 (0.56) | SLC2A1TRPC6KCNH2HTR1ASLC6A4 | |
| SCHEMBL5745036 | 0.87 | SLC2A1 (0.55) | SLC2A1TRPC6KCNH2PDE10A | |
| SCHEMBL6079906 | 0.87 | SLC2A1 (0.55) | SLC2A1TRPC6KCNH2PDE10A | |
| SCHEMBL6079813 | 0.87 | SLC2A1 (0.55) | SLC2A1TRPC6KCNH2PDE10A | |
| SCHEMBL6079978 | 0.84 | SLC2A1 (0.63) | SLC2A1KCNH2 | |
| SCHEMBL5746923 | 0.84 | SLC2A1 (0.60) | SLC2A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060041123-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041123-A1 | Antibacterial agents | NQO2, NRDC, IFNG | SLC2A1 4409/4885TRPC6 3722/4885KCNH2 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.